In vitro activity of 4′ -iodo-4′ -deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay

Raffaella Villa, Nadia Zaffaroni, Fernando Giuliani, Giovanni Colella, Ornella Sanfilippo, Rosella Silvestrini

Research output: Contribution to journalArticlepeer-review

Abstract

A short-term antimetabolic assay based upon the inhibition of incorporation of nucleic acid precursors was used to compare the cytotoxicity of a new halogenated anthracycline, 4′-iodo-4′-deoxydoxorubicin (IDX), with that of its parent compound doxorubicin (DX) on human colo-rectal carcinoma specimens. IDX showed a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose required to induce a significant antimetabolic effect for IDX was 1/10 that for DX.

Original languageEnglish
Pages (from-to)143-144
Number of pages2
JournalInvestigational New Drugs
Volume8
Issue number2
DOIs
Publication statusPublished - May 1990

Keywords

  • 4′-iodo-4′-deoxydoxorubicin
  • antimetabolic assay
  • colo-rectal cancer
  • doxorubicin

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'In vitro activity of 4′ -iodo-4′ -deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay'. Together they form a unique fingerprint.

Cite this